ERBB2 and neoplasm: Similarly, BsAbs targeting HER2 and CD3 have been demonstrated to induce tumor-specific cytotoxic T cell activity in HER2-positive breast cancer mouse models, significantly reducing tumor burden while maintaining minimal systemic toxicity [49].